InsidersTradesSigma
Follow the BioGene Therapeutics Inc. stock price and the full insider trade history of the company, a publicly traded company based in Canada. Shares are listed on CA CA, under the oversight of SEDI. Market capitalisation: €28.1bn. The latest transaction was reported on 10 June 2026 (00 - Opening Balance-Initial SEDI Report). Among the most active insiders: Van Deventer, Stephen. Every trade is accessible without an account.
Analysts rate BioGene Therapeutics Inc. Strong Buy (bullish), based on 16 analysts. Average price target: HK$42.58.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
BioGene Therapeutics Inc. is a company focused on developing gene therapies to treat genetic diseases. It is listed on the XTSE.